Peapod Lane Capital LLC Invests $1.03 Million in Nektar Therapeutics (NASDAQ:NKTR)

Peapod Lane Capital LLC acquired a new stake in shares of Nektar Therapeutics (NASDAQ:NKTR) during the 4th quarter, according to its most recent filing with the SEC. The institutional investor acquired 1,107,516 shares of the biopharmaceutical company’s stock, valued at approximately $1,030,000.

A number of other large investors also recently modified their holdings of NKTR. Valence8 US LP purchased a new stake in Nektar Therapeutics in the third quarter worth approximately $34,000. Intech Investment Management LLC bought a new stake in shares of Nektar Therapeutics in the 3rd quarter worth approximately $41,000. XTX Topco Ltd bought a new stake in shares of Nektar Therapeutics in the 3rd quarter worth approximately $46,000. Moloney Securities Asset Management LLC boosted its stake in shares of Nektar Therapeutics by 42.4% in the 4th quarter. Moloney Securities Asset Management LLC now owns 50,000 shares of the biopharmaceutical company’s stock valued at $46,000 after purchasing an additional 14,895 shares in the last quarter. Finally, HB Wealth Management LLC grew its holdings in shares of Nektar Therapeutics by 44.0% during the 4th quarter. HB Wealth Management LLC now owns 64,100 shares of the biopharmaceutical company’s stock valued at $60,000 after purchasing an additional 19,600 shares during the last quarter. 75.88% of the stock is owned by hedge funds and other institutional investors.

Nektar Therapeutics Stock Performance

NKTR stock opened at $0.73 on Thursday. The firm’s 50-day moving average price is $0.92 and its two-hundred day moving average price is $1.13. Nektar Therapeutics has a 12-month low of $0.63 and a 12-month high of $1.93.

Insider Buying and Selling

In other Nektar Therapeutics news, insider Mark Andrew Wilson sold 33,402 shares of the stock in a transaction that occurred on Monday, December 23rd. The stock was sold at an average price of $0.90, for a total value of $30,061.80. Following the completion of the sale, the insider now owns 351,892 shares in the company, valued at approximately $316,702.80. This trade represents a 8.67 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Howard W. Robin sold 46,995 shares of the business’s stock in a transaction that occurred on Tuesday, December 17th. The shares were sold at an average price of $1.01, for a total value of $47,464.95. Following the transaction, the chief executive officer now directly owns 1,195,710 shares in the company, valued at $1,207,667.10. This trade represents a 3.78 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 155,575 shares of company stock valued at $149,878 over the last ninety days. 3.71% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

NKTR has been the subject of several recent research reports. Piper Sandler initiated coverage on shares of Nektar Therapeutics in a research note on Monday, November 4th. They issued an “overweight” rating and a $7.00 price target for the company. B. Riley began coverage on Nektar Therapeutics in a research note on Wednesday, January 8th. They issued a “buy” rating and a $4.00 target price for the company. Finally, HC Wainwright restated a “buy” rating and set a $6.50 price target on shares of Nektar Therapeutics in a research report on Monday, January 13th. Two research analysts have rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, Nektar Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $4.08.

Nektar Therapeutics Company Profile

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer.